Where the disputes in this case are related to the use and performance of a drug and will ultimately affect the drug’s value as intellectual property, this action is properly designated as a business court case under G.S. § 7A-45.4(a)(5).
Plaintiff’s opposition to the business court designation is overruled.
Cardiorentis AG v. IQVIA Ltd. (Lawyers Weekly No. 020-041-18, 7 pp.) (James Gale, C.J.) J. Dickson Phillips III, Jonathan Krisko, Morgan Abbott, Dennis Tracey III and Allison Wuertz for plaintiff; Charles Marshall III, Charles Coble and Shepard O’Connell for defendants. 2018 NCBC 62